231 related articles for article (PubMed ID: 35419865)
1. Rising Interest in the Development of Metal Complexes in Cancer Immunotherapy.
Li ZY; Shen QH; Mao ZW; Tan CP
Chem Asian J; 2022 Jul; 17(13):e202200270. PubMed ID: 35419865
[TBL] [Abstract][Full Text] [Related]
2. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
Lazarević T; Rilak A; Bugarčić ŽD
Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
[TBL] [Abstract][Full Text] [Related]
3. Metallo-Drugs in Cancer Therapy: Past, Present and Future.
Lucaciu RL; Hangan AC; Sevastre B; Oprean LS
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235023
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Anticancer Ruthenium Complexes in Drug Discovery and Medicinal Chemistry.
Thota S
Mini Rev Med Chem; 2016; 16(10):771. PubMed ID: 27161007
[No Abstract] [Full Text] [Related]
5. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy.
Abid M; Shamsi F; Azam A
Mini Rev Med Chem; 2016; 16(10):772-86. PubMed ID: 26423699
[TBL] [Abstract][Full Text] [Related]
6. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
[TBL] [Abstract][Full Text] [Related]
7. Metal Complexes in Cancer Treatment: Journey So Far.
Kumar Singh A; Kumar A; Singh H; Sonawane P; Pathak P; Grishina M; Pal Yadav J; Verma A; Kumar P
Chem Biodivers; 2023 Apr; 20(4):e202300061. PubMed ID: 36824028
[TBL] [Abstract][Full Text] [Related]
8. Preface.
Prudhomme M
Anticancer Agents Med Chem; 2017; 17(1):3. PubMed ID: 28143384
[No Abstract] [Full Text] [Related]
9. Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes.
Liu P; Jia J; Zhao Y; Wang KZ
Mini Rev Med Chem; 2016; 16(4):272-89. PubMed ID: 26586123
[TBL] [Abstract][Full Text] [Related]
10. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes.
Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z
Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807
[TBL] [Abstract][Full Text] [Related]
11. Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives.
Lee SY; Kim CY; Nam TG
Drug Des Devel Ther; 2020; 14():5375-5392. PubMed ID: 33299303
[TBL] [Abstract][Full Text] [Related]
12. New applications of old metal-binding drugs in the treatment of human cancer.
Schmitt SM; Frezza M; Dou QP
Front Biosci (Schol Ed); 2012 Jan; 4(1):375-91. PubMed ID: 22202066
[TBL] [Abstract][Full Text] [Related]
13. Phosphoroorganic Metal Complexes in Therapeutics.
Demkowicz S; Kozak W; Daśko M; Rachon J
Mini Rev Med Chem; 2016; 16(17):1359-1373. PubMed ID: 27145849
[TBL] [Abstract][Full Text] [Related]
14. Rhodamine-modified fluorescent half-sandwich iridium and ruthenium complexes: potential application as bioimaging and anticancer agents.
Ma W; Guo L; Tian Z; Zhang S; He X; Li J; Yang Y; Liu Z
Dalton Trans; 2019 Apr; 48(15):4788-4793. PubMed ID: 30892340
[TBL] [Abstract][Full Text] [Related]
15. Addressing the gaps in homeostatic mechanisms of copper and copper dithiocarbamate complexes in cancer therapy: a shift from classical platinum-drug mechanisms.
Njenga LW; Mbugua SN; Odhiambo RA; Onani MO
Dalton Trans; 2023 May; 52(18):5823-5847. PubMed ID: 37021641
[TBL] [Abstract][Full Text] [Related]
16. Recent development of transition metal complexes with in vivo antitumor activity.
Liang JX; Zhong HJ; Yang G; Vellaisamy K; Ma DL; Leung CH
J Inorg Biochem; 2017 Dec; 177():276-286. PubMed ID: 28641893
[TBL] [Abstract][Full Text] [Related]
17. Serendipitous Synthesis of Five-Coordinated Half-Sandwich Aminoimine Iridium(III) and Ruthenium(II) Complexes and Their Application as Potent Anticancer Agents.
Du Q; Guo L; Ge X; Zhao L; Tian Z; Liu X; Zhang F; Liu Z
Inorg Chem; 2019 May; 58(9):5956-5965. PubMed ID: 30986046
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of fluorine and Naphthyridine-Based half-sandwich organoiridium/ruthenium complexes with bioimaging and anticancer activity.
Li J; Tian Z; Ge X; Xu Z; Feng Y; Liu Z
Eur J Med Chem; 2019 Feb; 163():830-839. PubMed ID: 30579123
[TBL] [Abstract][Full Text] [Related]
19. Anticancer metallodrugs: where is the next cisplatin?
Hanif M; Hartinger CG
Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
[TBL] [Abstract][Full Text] [Related]
20. Luminescent and Photofunctional Transition Metal Complexes: From Molecular Design to Diagnostic and Therapeutic Applications.
Lee LC; Lo KK
J Am Chem Soc; 2022 Aug; 144(32):14420-14440. PubMed ID: 35925792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
